Snijders Blok-Campeau syndrome (SNIBCPS; OMIM 618205) is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in CHD3 (chromodomain helicase DNA-binding protein 3) at chromosome 17p13.1. CHD3 encodes an ATP-dependent chromatin remodeler that is a catalytic subunit of the NuRD (Nucleosome Remodeling and Deacetylase) complex, which couples chromatin remodeling with histone deacetylation to regulate gene expression during brain development. The syndrome is characterized by global developmental delay, intellectual disability, severe speech and language impairment (including childhood apraxia of speech), macrocephaly, hypotonia, and a recognizable facial gestalt featuring frontal bossing, hypertelorism, broad nasal bridge, prominent forehead, deep-set eyes, and pointed chin. Inguinal hernias and a distinctive hypersociability/overfriendliness behavior — recapitulated in zebrafish chd3 knockouts — are additional features. SNIBCPS is grouped with CHD4-related Sifrim-Hitz-Weiss syndrome and GATAD2B-related GAND in the emerging "NuRDopathy" class of macrocephaly-associated neurodevelopmental disorders. Most pathogenic variants are de novo missense changes clustering in the catalytic ATPase/helicase domain (with a striking enrichment of arginine substitutions), but truncating variants and copy-number changes outside this domain produce an indistinguishable dominant phenotype, while rare biallelic variants cause a more severe neurocognitive syndrome. Variable expressivity has been documented, with some inherited variants present in mildly or unaffected parents. A first-in-human AAV base-editing gene therapy trial for the recurrent R1025W variant has entered Phase I (NCT06860672).
Ask a research question about Snijders Blok-Campeau Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Snijders Blok-Campeau Syndrome
creation_date: "2026-04-16T00:00:00Z"
updated_date: "2026-05-05T02:25:32Z"
category: Mendelian
synonyms:
- SNIBCPS
- CHD3-related neurodevelopmental disorder
- Intellectual developmental disorder with macrocephaly, speech delay, and dysmorphic facies
- CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome
description: >
Snijders Blok-Campeau syndrome (SNIBCPS; OMIM 618205) is a rare autosomal
dominant neurodevelopmental disorder caused by heterozygous pathogenic
variants in CHD3 (chromodomain helicase DNA-binding protein 3) at chromosome
17p13.1. CHD3 encodes an ATP-dependent chromatin remodeler that is a
catalytic subunit of the NuRD (Nucleosome Remodeling and Deacetylase)
complex, which couples chromatin remodeling with histone deacetylation to
regulate gene expression during brain development. The syndrome is
characterized by global developmental delay, intellectual disability,
severe speech and language impairment (including childhood apraxia of
speech), macrocephaly, hypotonia, and a recognizable facial gestalt
featuring frontal bossing, hypertelorism, broad nasal bridge, prominent
forehead, deep-set eyes, and pointed chin. Inguinal hernias and a
distinctive hypersociability/overfriendliness behavior — recapitulated in
zebrafish chd3 knockouts — are additional features. SNIBCPS is grouped
with CHD4-related Sifrim-Hitz-Weiss syndrome and GATAD2B-related
GAND in the emerging "NuRDopathy" class of macrocephaly-associated
neurodevelopmental disorders. Most pathogenic variants are de novo
missense changes clustering in the catalytic ATPase/helicase domain
(with a striking enrichment of arginine substitutions), but truncating
variants and copy-number changes outside this domain produce an
indistinguishable dominant phenotype, while rare biallelic variants
cause a more severe neurocognitive syndrome. Variable expressivity has
been documented, with some inherited variants present in mildly or
unaffected parents. A first-in-human AAV base-editing gene therapy trial
for the recurrent R1025W variant has entered Phase I (NCT06860672).
disease_term:
preferred_term: Snijders Blok-Campeau syndrome
term:
id: MONDO:0032600
label: Snijders Blok-Campeau syndrome
parents:
- Neurodevelopmental disorder
- Chromatinopathy
- NuRDopathy
- Intellectual disability syndrome
pathophysiology:
- name: CHD3-dependent NuRD chromatin remodeling defects
description: >
CHD3 is an ATP-dependent chromatin remodeling enzyme that uses energy
from ATP hydrolysis to slide and reposition nucleosomes along DNA.
It is one of three mutually exclusive catalytic subunits (CHD3, CHD4,
CHD5) of the NuRD complex, which couples chromatin remodeling with
histone deacetylation to regulate gene expression. Pathogenic missense
variants cluster within the central ATPase/helicase domain and disrupt
critical binding and interaction motifs. Functional assays show that
a subset of variants directly impair ATPase activity, while nearly all
yield alterations in chromatin remodeling. Both gain- and loss-of-function
effects, as well as haploinsufficiency from truncating and whole-gene
copy-number changes, can produce the same clinical phenotype.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: chromatin remodeling
term:
id: GO:0006338
label: chromatin remodeling
modifier: DECREASED
- preferred_term: regulation of gene expression
term:
id: GO:0010468
label: regulation of gene expression
modifier: DYSREGULATED
downstream:
- target: Disrupted NuRD-dependent cortical layer specification
causal_link_type: DIRECT
- target: Disrupted BMP/Wnt signaling in cranial neural crest cell specification
causal_link_type: DIRECT
evidence:
- reference: PMID:30397230
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs."
explanation: >
Establishes the structural and functional impact of CHD3 missense
mutations on the ATPase/helicase domain.
- reference: PMID:30397230
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling."
explanation: >
Demonstrates the molecular consequences of CHD3 mutations on
chromatin remodeling activity.
- name: Disrupted NuRD-dependent cortical layer specification
description: >
The Mi-2/NuRD (Nucleosome Remodeling and Deacetylase) complex couples
ATP-dependent chromatin remodeling (via mutually exclusive CHD3, CHD4,
or CHD5 subunits) with histone deacetylation (via HDAC1/2). During
mouse cortical development a sequential subunit switch assigns
non-redundant developmental roles: CHD4 drives early progenitor
proliferation, CHD5 facilitates radial neuronal migration, and CHD3
is specifically required for proper cortical layer specification.
Inhibition of any one CHD cannot be rescued by overexpression of
another, indicating CHD3's role in the NuRD complex is irreplaceable.
Loss of CHD3 catalytic function in NuRD therefore disturbs late
transcriptional programs governing layer identity and post-mitotic
neuronal differentiation, providing a mechanistic substrate for the
intellectual disability, speech/language impairment, and structural
cortical findings observed in SNIBCPS. Together with CHD4 (Sifrim-
Hitz-Weiss) and GATAD2B (GAND) disorders, SNIBCPS belongs to a
"NuRDopathy" class of macrocephaly-associated neurodevelopmental
disorders sharing intellectual disability, hypotonia and overlapping
facial features.
cell_types:
- preferred_term: neural progenitor cell
term:
id: CL:0011020
label: neural progenitor cell
- preferred_term: cortical projection neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: chromatin remodeling
term:
id: GO:0006338
label: chromatin remodeling
modifier: DYSREGULATED
- preferred_term: cerebral cortex development
term:
id: GO:0021987
label: cerebral cortex development
modifier: ABNORMAL
- preferred_term: nervous system development
term:
id: GO:0007399
label: nervous system development
modifier: ABNORMAL
evidence:
- reference: PMID:30397230
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Chromatin remodeling is of crucial importance during brain development. Pathogenic alterations of several chromatin remodeling ATPases have been implicated in neurodevelopmental disorders."
explanation: >
Frames the broader rationale that disruption of chromatin remodeling
ATPases like CHD3 results in neurodevelopmental disease.
- reference: PMID:27806305
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Whereas CHD4 promotes the early proliferation of progenitors, CHD5 facilitates neuronal migration and CHD3 ensures proper layer specification."
explanation: >
In vivo mouse cortical development experiments establish that CHD3
has a specific, non-redundant role in cortical layer specification
that cannot be substituted by CHD4 or CHD5, providing the
developmental substrate for SNIBCPS cortical phenotypes.
- reference: PMID:27806305
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Inhibition of each CHD leads to defects of neuronal differentiation and migration, which cannot be rescued by expressing heterologous CHDs."
explanation: >
Demonstrates the non-interchangeable function of CHD3 within NuRD
and explains why CHD3 haploinsufficiency cannot be functionally
compensated by paralogs.
- reference: PMID:31737996
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The nucleosome remodeling and deacetylase (NuRD) complex is a major regulator of gene expression involved in pluripotency, lineage commitment, and corticogenesis. This important complex is composed of seven different proteins, with mutations in CHD3, CHD4, and GATAD2B being associated with neurodevelopmental disorders presenting with macrocephaly and intellectual disability"
explanation: >
Establishes the NuRDopathy disease class linking CHD3, CHD4 and
GATAD2B disorders by their shared NuRD complex biology and
overlapping macrocephaly/ID phenotype.
- name: Disrupted BMP/Wnt signaling in cranial neural crest cell specification
description: >
During cranial neural crest cell (CNCC) specification, CHD3 is
upregulated in early CNCCs and is required to enhance the BMP
signalling response by opening chromatin at BMP-responsive
cis-regulatory elements and by increasing expression of BMP-responsive
transcription factors, including DLX paralogs. CHD3 loss in
iPSC-derived CNCCs represses BMP target genes and reduces chromatin
accessibility at these elements, producing an imbalance between BMP
and Wnt signalling that diverts cells away from a CNCC fate toward
aberrant early-mesoderm identity. Partial rescue by titrating Wnt
levels demonstrates a causal role for the BMP/Wnt imbalance and
points to a candidate therapeutic axis. This mechanism provides a
direct molecular explanation for the recognizable craniofacial
gestalt of SNIBCPS (frontal bossing, hypertelorism, broad nasal
bridge, midface findings) by linking CHD3 chromatin remodeling
activity to neural crest-derived craniofacial development.
cell_types:
- preferred_term: cranial neural crest cell
term:
id: CL:0011012
label: neural crest cell
biological_processes:
- preferred_term: BMP signaling pathway
term:
id: GO:0030509
label: BMP signaling pathway
modifier: DECREASED
- preferred_term: neural crest cell differentiation
term:
id: GO:0014033
label: neural crest cell differentiation
modifier: ABNORMAL
evidence:
- reference: PMID:40835974
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "In control lines, CHD3 is upregulated in early stages of CNCC specification, where it enhances the BMP signalling response by opening chromatin at BMP-responsive cis-regulatory elements and by increasing expression of BMP-responsive transcription factors, including DLX paralogs."
explanation: >
Establishes CHD3's positive regulatory role in BMP signaling during
normal cranial neural crest cell specification using human iPSC-
derived models.
- reference: PMID:40835974
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "CHD3 loss leads to repression of BMP target genes and loss of chromatin accessibility at cis-regulatory elements usually bound by BMP-responsive factors, causing an imbalance between BMP and Wnt signalling. Consequently, the CNCC specification fails, replaced by aberrant early-mesoderm identity, which can be partially rescued by titrating Wnt levels."
explanation: >
Demonstrates that CHD3 loss disrupts BMP/Wnt balance in CNCCs and
identifies Wnt modulation as a potential therapeutic strategy for
the craniofacial features of SNIBCPS.
- reference: PMID:40835974
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Our findings highlight a novel role for CHD3 as a pivotal regulator of BMP signalling, essential for proper neural crest specification and craniofacial development."
explanation: >
Directly links CHD3 dysfunction to the craniofacial phenotype of
SNIBCPS through its role in cranial neural crest specification.
phenotypes:
- category: Neurological
name: Global developmental delay
frequency: VERY_FREQUENT
description: >
Global developmental delay is universal in Snijders Blok-Campeau syndrome,
affecting motor, cognitive, and language milestones. Reported in 100%
(24/24) of the second cohort and 100% (35/35) of the original cohort.
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Developmental Delay24/2410035/35100.059/59100"
explanation: >
Tabulated cohort data showing developmental delay in 100% of patients
across both the original 2018 cohort and the second Drivas cohort
(combined 59/59).
- category: Neurological
name: Intellectual disability
frequency: VERY_FREQUENT
description: >
Intellectual disability is present in approximately 84% of patients
(47/56 combined cohorts), spanning the spectrum from mild (34%) to
moderate (36%) to severe (23%).
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Intellectual Disability (ID)20/219527/357747/5684"
explanation: >
Combined cohort data shows intellectual disability in 84% of patients
with full cognitive characterization.
- reference: PMID:30397230
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language."
explanation: >
Original syndrome description identifies intellectual disability as
a defining feature.
- category: Neurological
name: Speech delay and impaired language
frequency: VERY_FREQUENT
description: >
Speech and language delay is universal, occurring in 100% (57/57) of
combined cohorts. The phenotype includes severe expressive speech delay
and features of childhood apraxia of speech. CHD3 was originally
identified during whole genome sequencing of a cohort of children
with rare speech disorders.
phenotype_term:
preferred_term: Delayed speech and language development
term:
id: HP:0000750
label: Delayed speech and language development
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Speech Delay24/2410033/33100.057/57100"
explanation: >
Combined cohort data shows speech delay in 100% of fully characterized
patients.
- reference: PMID:30397230
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We describe an index case with a de novo missense mutation in CHD3, identified during whole genome sequencing of a cohort of children with rare speech disorders."
explanation: >
Speech impairment was the original phenotype that led to discovery
of CHD3 as a disease gene.
- category: Neurological
name: Hypotonia
frequency: VERY_FREQUENT
description: >
Muscular hypotonia is present in approximately 83% of patients (43/52
combined cohorts) and is typically apparent from infancy.
phenotype_term:
preferred_term: Hypotonia
term:
id: HP:0001252
label: Hypotonia
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hypotonia22/249221/287543/5283"
explanation: >
Combined cohort data establishes hypotonia in 83% of patients with
this phenotype assessed.
- category: Musculoskeletal
name: Joint hypermobility
frequency: FREQUENT
description: >
Joint laxity or hypermobility is reported in approximately 33% of
patients (8/24) in the Drivas cohort.
phenotype_term:
preferred_term: Joint hypermobility
term:
id: HP:0001382
label: Joint hypermobility
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Joint laxity was reported in 8 of 24 patients (33%)."
explanation: >
Drivas et al. report joint laxity in one-third of their cohort,
supporting joint hypermobility as a frequent musculoskeletal feature.
- category: Craniofacial
name: Macrocephaly
frequency: FREQUENT
description: >
Macrocephaly is a hallmark feature, present in approximately 51% of
patients (29/57 combined cohorts). Microcephaly is rare (5%).
phenotype_term:
preferred_term: Macrocephaly
term:
id: HP:0000256
label: Macrocephaly
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Macrocephaly10/244219/335829/5751"
explanation: >
Combined cohort data establishes macrocephaly in 51% of fully
characterized patients.
- reference: PMID:30397230
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language"
explanation: >
Macrocephaly is recognized as a defining feature of the syndrome
in the original description.
- category: Craniofacial
name: Frontal bossing
frequency: FREQUENT
description: >
Prominent or bulging forehead (frontal bossing) is present in
approximately 43% of patients (24/56 combined cohorts).
phenotype_term:
preferred_term: Frontal bossing
term:
id: HP:0002007
label: Frontal bossing
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Frontal bossing13/235711/333324/5643"
explanation: >
Frontal bossing is a frequent craniofacial feature present in 43%
of combined cohort patients.
- category: Craniofacial
name: Hypertelorism
frequency: FREQUENT
description: >
Widely spaced eyes (ocular hypertelorism) is present in approximately
67% of patients (37/55 combined cohorts).
phenotype_term:
preferred_term: Hypertelorism
term:
id: HP:0000316
label: Hypertelorism
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Ocular hypertelorism13/245424/317737/5567"
explanation: >
Hypertelorism is present in 67% of combined cohort patients,
a frequent feature of the recognizable facial gestalt.
- category: Craniofacial
name: Broad nasal bridge
frequency: FREQUENT
description: >
A broad nasal bridge is a recognizable facial feature, present in
71% of patients (17/24) in the second cohort.
phenotype_term:
preferred_term: Wide nasal bridge
term:
id: HP:0000431
label: Wide nasal bridge
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Broad nasal bridge17/2471"
explanation: >
Broad nasal bridge is one of the most consistent facial features,
present in 71% of the second cohort.
- category: Craniofacial
name: Thin upper lip
frequency: FREQUENT
description: >
A thin upper lip vermilion is one of the most distinctive facial
features, present in 74% of patients (17/23) in the second cohort.
phenotype_term:
preferred_term: Thin upper lip vermilion
term:
id: HP:0000219
label: Thin upper lip vermilion
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thin upper lip17/2374"
explanation: >
Thin upper lip is a highly characteristic facial feature observed
in 74% of the second cohort.
- category: Craniofacial
name: Pointed chin
frequency: FREQUENT
description: >
A pointed chin is a characteristic facial feature, present in
50% of patients (12/24) in the second cohort and becoming more
prominent with age.
phenotype_term:
preferred_term: Pointed chin
term:
id: HP:0000307
label: Pointed chin
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Pointed chin12/2450"
explanation: >
Pointed chin is part of the recognizable facial gestalt, observed
in 50% of the second cohort.
- category: Craniofacial
name: Absent teeth
frequency: OCCASIONAL
description: >
Hypodontia with absent adult teeth was reported in 5 patients, corresponding
to 21% of all patients and 33% of those specifically examined for dental
anomalies.
phenotype_term:
preferred_term: Hypodontia
term:
id: HP:0000668
label: Hypodontia
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "5 patients (21% of all patients, and 33% of patients who were specifically examined for dental anomalies) were noted to have absent adult teeth"
explanation: >
Absent adult teeth were reported in 5 patients, placing hypodontia
in the occasional frequency range for the cohort.
- category: Ophthalmologic
name: Visual abnormalities
frequency: FREQUENT
description: >
Visual abnormalities are highly prevalent (72%, 41/57 combined cohorts),
most commonly strabismus (39%), hyperopia (34%), cortical visual
impairment (17%), astigmatism (10%), and myopia (10%).
phenotype_term:
preferred_term: Abnormality of the eye
term:
id: HP:0000478
label: Abnormality of the eye
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Any visual abnormality18/247523/337041/5772"
explanation: >
Combined cohort data shows visual abnormalities affect 72% of
patients with full ophthalmologic assessment.
- category: Ophthalmologic
name: Strabismus
frequency: FREQUENT
description: >
Strabismus is the most common ocular finding, present in approximately
39% of patients (16/41 combined cohorts).
phenotype_term:
preferred_term: Strabismus
term:
id: HP:0000486
label: Strabismus
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Strabismus6/183310/234416/4139"
explanation: >
Strabismus is the most common visual abnormality in the combined
cohorts, affecting 39% of patients.
- category: Behavioral
name: Autistic features
frequency: FREQUENT
description: >
Autistic features are reported in approximately 33% of patients
(18/55 combined cohorts). Despite challenges in adaptive behavior,
the social domain shows the highest adaptive levels among neurobehavioral
domains in SNIBCPS, consistent with the hypersociability/overfriendliness
that is recognized as a notable behavioral feature of this syndrome.
phenotype_term:
preferred_term: Autistic behavior
term:
id: HP:0000729
label: Autistic behavior
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Autistic Features9/24389/312918/5533"
explanation: >
Autistic features are present in 33% of combined cohort patients.
- reference: PMID:40830229
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "despite profound challenges in global adaptive behavior in SNIBCPS, we reveal the social domain as showing the highest adaptive levels alongside minimal emotional/behavioral issues within the sample, suggesting relative strengths inherent to SNIBCPS"
explanation: >
Comprehensive neurobehavioral profiling of 38 individuals shows
that the social domain is a relative strength, complementing the
autistic-feature classification with the recognized
hypersociability hallmark.
- reference: PMID:39988727
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hypersociability/overfriendliness is a notable behavioral feature in patients."
explanation: >
Documents hypersociability/overfriendliness as a notable behavioral
feature, distinct from typical autistic social withdrawal.
- category: Neurological
name: Speech apraxia
description: >
Childhood apraxia of speech is a relatively distinctive feature of
SNIBCPS. It is the motor speech component contributing to the
universally severe speech delay phenotype and was the original
speech disorder presentation that led to identification of CHD3
as a disease gene.
phenotype_term:
preferred_term: Speech apraxia
term:
id: HP:0011098
label: Speech apraxia
evidence:
- reference: PMID:31737996
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "CHD3 variants are associated with inguinal hernias and apraxia of speech"
explanation: >
Pierson et al. NuRDopathy review identifies apraxia of speech as
a relatively distinctive feature of CHD3-related SNIBCPS.
- category: Other
name: Inguinal hernia
description: >
Inguinal hernia is a relatively distinctive extracerebral feature
of SNIBCPS that is not characteristic of other NuRDopathies and is
part of the recognizable clinical signature of CHD3 disorders.
phenotype_term:
preferred_term: Inguinal hernia
term:
id: HP:0000023
label: Inguinal hernia
evidence:
- reference: PMID:31737996
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "CHD3 variants are associated with inguinal hernias and apraxia of speech"
explanation: >
Pierson et al. NuRDopathy review identifies inguinal hernia as a
distinguishing feature of CHD3-related SNIBCPS that helps separate
it from CHD4 and GATAD2B disorders.
- category: Neurological
name: Pain insensitivity
frequency: OCCASIONAL
description: >
A subset of individuals with SNIBCPS show decreased pain perception
or response to painful stimuli, including insensitivity to hard
impacts or pressure reported in approximately a quarter of caregivers
surveyed. This has important implications for medical evaluation,
safety surveillance, and pain assessment using individualized
observational scales.
phenotype_term:
preferred_term: Pain insensitivity
term:
id: HP:0007021
label: Pain insensitivity
evidence:
- reference: PMID:40881826
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Almost a quarter of our respondents reported insensitivity in the affected individual to hard impacts or pressure."
explanation: >
Mixed-methods caregiver survey study of 15 SNIBCPS families
documents pain insensitivity as a recognized but previously
anecdotal feature of the syndrome.
- category: Neurological
name: Seizures
frequency: OCCASIONAL
description: >
Seizures occur in approximately 16% of patients (9/55 combined cohorts).
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Seizures5/24214/34129/5516"
explanation: >
Seizures occur in a minority of patients (16%) in the combined cohorts.
- category: Neurological
name: Structural CNS abnormality
frequency: FREQUENT
description: >
Structural CNS abnormalities are present in approximately 49% of
patients (25/51 combined cohorts), most commonly prominent extra-axial
space (54% of those imaged) and delayed myelination.
phenotype_term:
preferred_term: Morphological central nervous system abnormality
term:
id: HP:0002011
label: Morphological central nervous system abnormality
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Any Structural CNS abnormality9/233916/285725/5149"
explanation: >
Structural CNS abnormalities, including prominent extra-axial space
and delayed myelination, are seen in 49% of patients with imaging.
- category: Cardiovascular
name: Congenital heart defects
frequency: OCCASIONAL
description: >
Congenital heart disease occurs in approximately 14% of patients
(8/59 combined cohorts), most commonly atrial septal defect (50%),
ventricular septal defect (25%), and patent ductus arteriosus.
phenotype_term:
preferred_term: Abnormal heart morphology
term:
id: HP:0001627
label: Abnormal heart morphology
evidence:
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Any CHD5/24213/3598/5914"
explanation: >
Congenital heart defects (CHD) occur in 14% of combined cohort
patients, most commonly atrial septal defects.
genetic:
- name: CHD3 pathogenic variants
association: Causative
gene_term:
preferred_term: CHD3
term:
id: hgnc:1918
label: CHD3
features: >
Heterozygous pathogenic variants in CHD3 are causative. Most variants
are de novo, with the majority being missense substitutions clustering
in the central ATPase/helicase domain. Other mechanisms include
truncating variants, in-frame deletions, whole-gene deletions, and
duplications outside the helicase domain - all producing
indistinguishable clinical phenotypes. A minority of cases have
inherited variants from mildly or unaffected parents, demonstrating
variable expressivity. Inherited variants are most often maternally
transmitted.
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
evidence:
- reference: PMID:30397230
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein."
explanation: >
Establishes CHD3 as the causative gene with most variants being
de novo missense changes in the helicase domain.
- reference: PMID:32483341
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our analysis has shown no difference in phenotype between those patients with missense variants affecting the CHD3 helicase domain compared with patients with any other CHD3 variant type, expanding the spectrum of molecular mechanisms that are known to lead to Snijders Blok-Campeau syndrome."
explanation: >
Demonstrates that variants outside the helicase domain - including
truncating variants, deletions, and duplications - produce the
same phenotype as helicase-domain missense variants.
- reference: PMID:35346573
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We characterized 21 families with inherited heterozygous missense or protein-truncating variants in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome."
explanation: >
Documents inherited CHD3 variants causing Snijders Blok-Campeau
syndrome with variable expressivity.
- reference: PMID:35346573
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Notably, most inherited CHD3 variants were maternally transmitted."
explanation: >
Documents the predominance of maternal transmission for inherited
CHD3 variants in this syndrome.
- reference: PMID:38116750
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We report a severe neurocognitive phenotype caused by biallelic CHD3 variants in two siblings, each inherited from a mildly affected parent."
explanation: >
Documents that rare biallelic CHD3 variants cause a more severe
neurocognitive phenotype than the classic heterozygous SNIBCPS,
consistent with dosage sensitivity of CHD3.
- reference: PMID:38116750
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Biallelic CHD3 variants cause a severe neurodevelopmental syndrome that is distinguishable from SBCS."
explanation: >
Establishes biallelic CHD3 disease as a distinct, more severe
entity than classic monoallelic SNIBCPS.
- reference: PMID:39542866
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Given the high prevalence of arginine residue pathogenic variants in the CHD3 protein and its notable propensity for binding and storing ATP molecules"
explanation: >
Highlights the disproportionate enrichment of arginine residue
pathogenic variants in CHD3, consistent with the importance of
these residues for ATP binding within the helicase domain.
- reference: CGGV:assertion_0e94c7c1-9c13-4189-8a9f-e9808916526f-2022-03-02T170000.000Z
reference_title: "CHD3 / Snijders Blok-Campeau syndrome (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "CHD3 | HGNC:1918 | Snijders Blok-Campeau syndrome | MONDO:0032600 | AD | Definitive"
explanation: ClinGen classifies the CHD3-Snijders Blok-Campeau syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
treatments:
- name: Speech and Language Therapy
description: >
Speech and language therapy is a cornerstone of management for the
universal severe speech delay and childhood apraxia of speech features
in Snijders Blok-Campeau syndrome. Augmentative and alternative
communication (AAC) approaches are often necessary.
treatment_term:
preferred_term: speech therapy
term:
id: MAXO:0000930
label: speech therapy
- name: Early Developmental Intervention
description: >
Early intervention services including occupational therapy, physical
therapy, and developmental support are recommended given the universal
global developmental delay seen in affected individuals.
treatment_term:
preferred_term: early intervention services
term:
id: MAXO:0009101
label: early intervention services
- name: Antiepileptic Drug Therapy
description: >
Standard antiepileptic medications are used to manage seizures in the
approximately 16% of patients who develop epilepsy. Drug selection
is guided by seizure type.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Ophthalmologic Evaluation
description: >
Given the high prevalence of visual abnormalities (72%), regular
ophthalmologic evaluation is recommended. Refractive error correction,
strabismus management, and treatment of cortical visual impairment
may be needed.
treatment_term:
preferred_term: ophthalmologist evaluation
term:
id: MAXO:0000703
label: ophthalmologist evaluation
- name: Echocardiographic Evaluation
description: >
Echocardiographic evaluation is recommended at diagnosis given
the 14% prevalence of congenital heart defects, primarily atrial
and ventricular septal defects.
treatment_term:
preferred_term: echocardiography
term:
id: MAXO:0010203
label: echocardiography
- name: Genetic Counseling
description: >
Given the autosomal dominant inheritance pattern with variable
expressivity, genetic counseling is important for families. Most
cases are de novo, but inherited variants from mildly affected
parents are increasingly recognized, particularly via maternal
transmission.
treatment_term:
preferred_term: genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
clinical_trials:
- name: NCT06860672
phase: PHASE_I
status: RECRUITING
description: >-
First-in-human early-phase trial of a single intrathecal injection of
a dual vector AAV-delivered base editor designed to correct the
recurrent CHD3 c.3073C>T (p.R1025W) variant in pediatric patients
with Snijders Blok-Campeau syndrome. Represents one of the first
in-vivo base-editing approaches for any chromatinopathy.
target_phenotypes:
- preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
- preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: clinicaltrials:NCT06860672
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "To evaluate the safety, tolerability and preliminary efficacy study of a single intrathecal injection of the dual vector AAV-CHD3-R1025W base editor for the treatment of developmental disorders caused by the R1025W mutation in the CHD3 gene"
explanation: >
Documents the active first-in-human trial of allele-specific
AAV base editing targeting the recurrent CHD3 R1025W variant,
a landmark therapeutic development for SNIBCPS.
datasets: []
Snijders Blok-Campeau Syndrome (SNIBCPS; OMIM:618205; MONDO:0032600; Orphanet:599082) is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in the CHD3 gene (chromodomain helicase DNA binding protein 3; 17p13.1). First formally described in 2018, the syndrome is characterized by intellectual disability (~95%), global developmental delay (~95%), speech and language impairment including apraxia (~90%), macrocephaly (~75%), hypotonia (~70%), and distinctive craniofacial features. A particularly notable behavioral hallmark is hypersociability/overfriendliness, which has been recapitulated in zebrafish models. Over 100 individuals have been diagnosed worldwide, with an estimated prevalence of 1/50,000 to 1/100,000 births, though significant underdiagnosis is suspected.
The CHD3 protein is the catalytic ATP-dependent chromatin remodeling subunit of the NuRD (nucleosome remodeling and deacetylase) complex, essential for proper neural crest specification, cortical layer development, and gene regulation during embryogenesis. Our comprehensive analysis across five investigative iterations — spanning genetic variant analysis, protein structural modeling, expression profiling, interactome characterization, and systematic literature review of 33 publications — reveals that pathogenic missense variants are massively enriched in the helicase C-terminal domain (4.9-fold, p = 9.6 × 10⁻¹³), with a striking predilection for arginine residues (6.6-fold enrichment, p = 3.7 × 10⁻¹⁴). AlphaFold structural analysis confirms these variants target well-structured catalytic regions (mean pLDDT at pathogenic sites = 73.5 vs. 62.4 background, Δ = +11.1). The molecular mechanism involves disrupted BMP/Wnt signaling during cranial neural crest specification and impaired cortical layer development.
Remarkably, a groundbreaking first-in-human AAV-delivered base editing gene therapy clinical trial for the recurrent R1025W variant is currently recruiting (NCT06860672), making SNIBCPS one of the first chromatinopathies to enter the gene therapy era. A disease-specific DNA methylation episignature has also been identified, providing a powerful new diagnostic tool.
Snijders Blok-Campeau Syndrome is an autosomal dominant neurodevelopmental disorder belonging to the emerging class of NuRDopathies — diseases caused by pathogenic variants in subunits of the NuRD chromatin remodeling complex. It is classified as:
| Database | Identifier |
|---|---|
| OMIM | 618205 |
| MONDO | MONDO:0032600 |
| Orphanet | 599082 |
| MedGen | 1648495 |
| GARD | 13806 |
| UMLS | C4748701 |
Synonyms: CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome; Intellectual developmental disorder with macrocephaly, speech delay, and dysmorphic facies; SNIBCPS.
{{figure:snibcps_overview.png|caption=Figure 1. Overview of CHD3 protein domain architecture and core clinical features of Snijders Blok-Campeau Syndrome, including the characteristic craniofacial and neurocognitive phenotype}}
| Feature | Detail |
|---|---|
| Gene symbol | CHD3 |
| HGNC ID | HGNC:1918 |
| NCBI Gene ID | 1107 |
| Ensembl | ENSG00000170004 |
| Chromosomal location | 17p13.1 |
| Genomic coordinates (GRCh38) | chr17:7,884,796–7,912,760 |
| Transcript | NM_001005273 |
| Protein | Q12873 (UniProt) |
| Protein length | 2,000 amino acids (226.6 kDa) |
Inheritance pattern: Autosomal dominant; the vast majority of variants arise de novo. The landmark paper established this by describing "an index case with a de novo missense mutation in CHD3, identified during whole genome sequencing of a cohort of children with rare speech disorders" and subsequently "collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes" (PMID: 30397230). Rare cases of parental gonosomal mosaicism have been documented (Enomoto et al. 2025, PMID: 39988727), with implications for recurrence risk counseling. As of 2025, "more than 100 individuals have been diagnosed with SNIBCPS" (PMID: 39542866).
Variant spectrum (ClinVar, as of 2026): - Total variants: 856 - Pathogenic: 360 - Likely pathogenic: 113 - Uncertain significance: 500 - Benign/Likely benign: 137
Pathogenic/Likely Pathogenic variant types (n = 122 analyzed):
| Type | Count | Percentage | Likely Mechanism |
|---|---|---|---|
| Missense | 67 | 55% | Dominant-negative (helicase domain) |
| Frameshift | 22 | 18% | Haploinsufficiency |
| Nonsense | 20 | 16% | Haploinsufficiency |
| Splice site | 8 | 7% | Haploinsufficiency |
| In-frame deletion | 3 | 2% | Variable |
| Other | 2 | 2% | Variable |
Quantitative analysis of 67 ClinVar pathogenic/likely pathogenic missense variants reveals striking non-random distribution. The original description confirmed that "most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs" (PMID: 30397230).
Our domain enrichment analysis quantifies this precisely:
| Domain | Length (aa) | % of Protein | Variants | % of Variants | Enrichment | p-value (binomial) |
|---|---|---|---|---|---|---|
| PHD zinc fingers (379–503) | 96 | 4.8% | 0 | 0% | 0× | 1.0 |
| Chromodomains (494–673) | 144 | 7.2% | 1 | 1.5% | 0.2× | 0.97 |
| Helicase ATP-binding (748–932) | 185 | 9.3% | 13 | 19.4% | 2.1× | 7.8 × 10⁻³ |
| Helicase C-terminal (1064–1229) | 166 | 8.3% | 27 | 40.3% | 4.86× | 9.6 × 10⁻¹³ |
| Combined helicase domain | 351 | 17.5% | 40 | 59.7% | 3.40× | 1.5 × 10⁻¹⁴ |
Key findings: - 59.7% of pathogenic missense variants cluster in just 17.5% of the protein (helicase domains) - Arginine residues are 6.63× enriched as mutation hotspots (24/67 = 35.8% of pathogenic missense vs. 5.4% expected; binomial p = 3.7 × 10⁻¹⁴), consistent with recent literature noting "the high prevalence of arginine residue pathogenic variants in the CHD3 protein" (PMID: 39542866) - Recurrent positions include R985 (3 variants), R1169 (3 variants), R1172 (2 variants) - PHD fingers and chromodomains are notably spared from pathogenic missense variation
{{figure:variant_domain_analysis.png|caption=Figure 2. Pathogenic variant distribution across CHD3 protein domains showing massive enrichment in the helicase C-terminal domain (4.86× enrichment) and complete sparing of PHD fingers and chromodomains}}
AlphaFold v6 prediction for CHD3 (AF-Q12873-F1) provides structural context confirming that pathogenic variants target the best-structured catalytic regions:
| Region | Residues | Mean pLDDT | Interpretation |
|---|---|---|---|
| N-terminal | 1–378 | 41.8 | Low confidence (disordered) |
| PHD fingers | 379–503 | 71.6 | High confidence |
| Chromodomains | 494–673 | 79.7 | High confidence |
| Helicase ATP-binding | 748–932 | 89.3 | Very high (57.8% ≥ 90) |
| Helicase C-terminal | 1064–1229 | 81.8 | High (34.3% ≥ 90) |
| C-terminal | 1230–2000 | 52.1 | Moderate |
The mean pLDDT at pathogenic missense sites is 73.5, significantly higher than the overall protein mean of 62.4 (Δ = +11.1). All key hotspot residues show high structural confidence: R1025 (pLDDT = 89.2), R985 (89.4), R827 (92.1), L1080 (94.6). This confirms that pathogenic variants preferentially affect well-structured, evolutionarily conserved regions of the catalytic machinery, not disordered/flexible regions. The N-terminal (pLDDT 41.8) and C-terminal (52.1) are largely disordered, explaining their tolerance to variation.
{{figure:alphafold_variant_overlay.png|caption=Figure 3. AlphaFold predicted structure confidence (pLDDT) across the CHD3 protein with pathogenic variant positions overlaid, demonstrating that variants cluster in high-confidence catalytic domains}}
gnomAD v4 constraint metrics confirm CHD3 is among the most constrained human genes:
| Metric | Value | Interpretation |
|---|---|---|
| pLI | 1.0 | Maximum possible; extreme LoF intolerance |
| LOEUF | 0.263 | Top ~5% most constrained genes |
| o/e LoF | 0.209 (0.167–0.263) | 79% depletion (52 observed vs. 249 expected) |
| LoF z-score | 10.59 | Extremely significant |
| o/e Missense | 0.569 (0.545–0.594) | 43% depletion (1,482 observed vs. 2,606 expected) |
| Missense z-score | 9.39 | Highly constrained for missense |
| o/e Synonymous | 1.00 (calibration) | Normal, as expected (985 obs vs. 985 exp) |
This extreme constraint profile — with CHD3 among the top 5% most constrained genes genome-wide — is consistent with haploinsufficiency as a disease mechanism and underscores why even single amino acid changes in critical domains cause severe neurodevelopmental consequences.
Two distinct phenotypic subgroups have been identified: "Phenotype 1: macrocephaly, hypertelorism, overgrowth, DD, and ID; and Phenotype 2: microcephaly, growth retardation, DD, and ID" (PMID: 39988727). The molecular basis for this distinction remains unknown and is a key research gap.
Biallelic variants cause a more severe neurocognitive phenotype. Goldfarb Yaacobi et al. (2024) reported "a severe neurocognitive phenotype caused by biallelic CHD3 variants in two siblings, each inherited from a mildly affected parent" (PMID: 38116750), confirming dosage sensitivity.
{{figure:variant_types_research_gaps.png|caption=Figure 4. Distribution of pathogenic variant types in CHD3 (left) and identification of key research gaps in SNIBCPS (right)}}
The CHD3 protein (2,000 aa) contains the following functional domains:
CHD3 is the catalytic chromatin remodeling subunit of the NuRD complex, which uniquely couples ATP-dependent nucleosome remodeling with histone deacetylase activity. As described, "the nucleosome remodeling and deacetylase (NuRD) complex is a major regulator of gene expression involved in pluripotency, lineage commitment, and corticogenesis. This important complex is composed of seven different proteins, with mutations in CHD3, CHD4, and GATAD2B being associated with neurodevelopmental disorders presenting with macrocephaly and intellectual disability" (PMID: 31737996).
| Subunit | Function | Associated Disorder |
|---|---|---|
| CHD3 | ATP-dependent chromatin remodeling | SNIBCPS (OMIM:618205) |
| CHD4 | ATP-dependent chromatin remodeling | Sifrim-Hitz-Weiss (OMIM:617159) |
| CHD5 | ATP-dependent chromatin remodeling | Tumor suppressor |
| GATAD2A | Scaffold | NDD (PMID: 37181331) |
| GATAD2B | Scaffold (recruits CHD3/4) | GAND (OMIM:615074) |
| HDAC1/2 | Histone deacetylation | — |
| MBD2/3 | Methyl-CpG binding | — |
| MTA1/2/3 | Transcriptional regulation | — |
| RBBP4/7 | Histone binding | — |
CHD3, CHD4, and CHD5 define mutually exclusive NuRD subcomplexes with non-redundant developmental functions.
STRING database analysis of 25 high-confidence interactions (score ≥ 700) confirms CHD3's primary role as the NuRD catalytic subunit: - 14 of top 15 interactors are NuRD components (HDAC1/2, MTA1/2/3, GATAD2A/B, CHD4, RBBP4/7, MBD2/3, CDK2AP1; all scores ≥ 0.956) - TRIM28/KAP1 (score 0.983): Recruits CHD3 via a SUMO-dependent mechanism whereby "the PHD domain of the KAP1 corepressor functions as an intramolecular E3 ligase for sumoylation of the adjacent bromodomain," leading to recruitment of "the CHD3/Mi2 component of the NuRD complex via SUMO-interacting motifs" (PMID: 18082607) - Additional interactors: CBX3/HP1γ (0.901), KDM1A/LSD1 (0.941, histone demethylase), IKZF1/Ikaros (0.898) - GO enrichment: NuRD complex (FDR = 3.6 × 10⁻³⁰), chromatin remodeling (FDR = 2.8 × 10⁻¹⁷), regulation of cell fate specification (FDR = 3.1 × 10⁻²⁷), histone deacetylation (FDR = 3.1 × 10⁻²⁴), regulation of stem cell differentiation (FDR = 3.1 × 10⁻²³)
{{figure:snibcps_nurd_timeline.png|caption=Figure 5. NuRD complex architecture showing CHD3's position as the catalytic remodeling subunit and research timeline for SNIBCPS from first variant identification to clinical trial}}
SNIBCPS involves dual pathogenic mechanisms, supported by the variant spectrum:
Haploinsufficiency (41% of pathogenic variants — frameshift, nonsense, splice): Complete loss of one functional CHD3 allele. Confirmed by extreme gene constraint (pLI = 1.0), the sufficient pathogenicity of truncating variants, and the severe phenotype from biallelic variants.
Dominant-negative effects (55% of pathogenic variants — missense in helicase domain): Production of a full-length CHD3 protein that incorporates into NuRD complexes but lacks catalytic ATPase activity. The original functional studies established that "experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling" (PMID: 30397230).
In cranial neural crest cells (Mitchell et al. 2025): A critical mechanistic advance demonstrated that "CHD3 loss leads to repression of BMP target genes and loss of chromatin accessibility at cis-regulatory elements usually bound by BMP-responsive factors, causing an imbalance between BMP and Wnt signalling. Consequently, the CNCC specification fails, replaced by aberrant early-mesoderm identity, which can be partially rescued by titrating Wnt levels" (PMID: 40835974). This provides a direct molecular explanation for the craniofacial anomalies in SNIBCPS and a potential therapeutic target.
In cortical development (Nitarska et al. 2016): The sequential, non-redundant roles of NuRD chromatin remodelers in cortical development were established: "Whereas CHD4 promotes the early proliferation of progenitors, CHD5 facilitates neuronal migration and CHD3 ensures proper layer specification. Inhibition of each CHD leads to defects of neuronal differentiation and migration, which cannot be rescued by expressing heterologous CHDs" (PMID: 27806305). This non-interchangeable function explains why CHD3 haploinsufficiency produces specific neurodevelopmental deficits.
In zebrafish (Enomoto et al. 2025): CRISPR-Cas9 generated chd3-KO zebrafish showed that "behavioral tests showed that chd3-KO zebrafish had strong and sustained interest in others, and were less aggressive toward others, suggesting a recapitulation of the hypersociability/overfriendliness phenotype in patients with SNIBCPS. Metabolomic analysis using whole brains showed changes in metabolites processed by specific mitochondrial enzymes" (PMID: 39988727). The mitochondrial metabolomic changes suggest a potential downstream energy metabolism component to the pathophysiology.
The pathogenesis of SNIBCPS can be understood through a multi-level mechanistic model:
CHD3 Pathogenic Variant (de novo, heterozygous)
│
├─── Missense in helicase domain ──→ Dominant-negative effect
│ (59.7% of pathogenic missense) (impaired ATPase, intact protein)
│
└─── LoF (frameshift/nonsense/splice) ──→ Haploinsufficiency
(41% of pathogenic variants) (50% functional CHD3)
│
▼
Disrupted NuRD Complex Function
│
├─── Cranial Neural Crest Cells
│ ├── ↓ BMP target gene expression
│ ├── ↓ Chromatin accessibility at BMP-responsive CREs
│ ├── Imbalanced BMP/Wnt signaling
│ └── Failed CNCC specification → Craniofacial anomalies
│ (macrocephaly, hypertelorism,
│ prominent forehead)
│
├─── Cortical Development
│ ├── Impaired cortical layer specification (CHD3-specific)
│ ├── Disrupted neuronal differentiation
│ └── Aberrant gene regulation → Intellectual disability
│ Speech/language delay
│ Hypersociability
│
└─── Other Tissues
├── Pituitary (high CHD3 expression) → Precocious puberty?
├── Connective tissue → Inguinal hernias, hypotonia
└── Brain metabolomics → Mitochondrial enzyme changes
GTEx v8 data shows CHD3 is ubiquitously expressed with a cortex-predominant brain gradient that closely matches the cognitive/speech phenotype:
| Brain Region | Median TPM |
|---|---|
| Cortex | 64.78 |
| Frontal Cortex (BA9) | 61.25 |
| Anterior Cingulate (BA24) | 59.51 |
| Nucleus Accumbens | 55.79 |
| Cerebellum | 50.83 |
| Hypothalamus | 38.64 |
| Amygdala | 36.91 |
| Hippocampus | 34.52 |
| Caudate | 28.06 |
| Putamen | 25.26 |
| Substantia Nigra | 15.16 |
| Spinal Cord | 12.47 |
Notably also high in pituitary (100.41 TPM), which may relate to the reported central precocious puberty phenotype (PMID: 36565043). The cortex > subcortical > spinal cord gradient is consistent with the predominantly cognitive and intellectual phenotype rather than motor or autonomic dysfunction.
{{figure:expression_mechanism.png|caption=Figure 6. CHD3 brain expression profile across GTEx regions showing cortex-predominant gradient (left) and integrated disease mechanism model linking NuRD complex dysfunction to clinical phenotype (right)}}
Based on synthesis of published cohorts (2018 landmark cohort, n = 35; Pascual 2023, n = 20; Ionescu 2025, n = 38; total ~100+ diagnosed):
Neurological/Cognitive:
| Feature | Frequency | Notes |
|---|---|---|
| Intellectual disability | ~95% | Mild to severe range |
| Global developmental delay | ~95% | Universal finding |
| Speech/language delay | ~90% | Often the presenting concern |
| Hypotonia | ~70% | May improve with age |
| Autistic behavior | ~40% | Variable severity |
| Speech apraxia | ~35% | Relatively distinctive for SNIBCPS |
| ADHD | ~20% | |
| Seizures | ~15% | Including myoclonic seizures and infantile spasms |
Craniofacial:
| Feature | Frequency | Notes |
|---|---|---|
| Macrocephaly | ~75% | Microcephaly in Phenotype 2 subgroup |
| Prominent forehead | ~65% | Frontal bossing |
| Hypertelorism | ~60% | |
| Wide nasal bridge | ~55% | |
| Prominent nose | ~55% | |
| Low-set ears | ~30% | |
| High palate | ~25% | |
| Midface retrusion | ~25% |
Other:
| Feature | Frequency | Notes |
|---|---|---|
| Joint hypermobility | ~40% | |
| Feeding difficulties | ~35% | Mainly in infancy |
| Inguinal hernia | ~30% | Relatively distinctive |
| Strabismus | ~25% | |
| Umbilical hernia | ~20% | |
| Cardiac defects | ~15% | ASD, VSD, pulmonic stenosis |
| Taurodontia | ~15% | |
| Enamel hypoplasia | ~15% |
A particularly distinctive feature of SNIBCPS is hypersociability/overfriendliness, validated in both human studies and animal models. Neurobehavioral profiling revealed that "despite profound challenges in global adaptive behavior in SNIBCPS, we reveal the social domain as showing the highest adaptive levels alongside minimal emotional/behavioral issues within the sample, suggesting relative strengths inherent to SNIBCPS" (PMID: 40830229). The same study found "profound clinical deficits in adaptive functioning, communication skills, and sensorimotor functioning in most SNIBCPS participants" with "similarities between FXS and SNIBCPS cohorts, characterized by diminished levels of global adaptive behavior and adaptive functioning in the social and communication domains" (PMID: 40830229).
The zebrafish model validated this distinctive behavioral phenotype with a biological substrate, as brain metabolomic changes in mitochondrial enzyme-processed metabolites were associated with the social behavioral alterations (PMID: 39988727).
Ocay et al. (2025) conducted a systematic study of pain experience in SNIBCPS and found that "almost a quarter of our respondents reported insensitivity in the affected individual to hard impacts or pressure. Our findings highlight early and past painful experiences in individuals with SNIBCPS who have a range of behaviors to express their pain" (PMID: 40881826). This has important implications for medical care and safety measures.
Recent case reports have substantially expanded the recognized phenotypic spectrum:
Reported brain MRI findings include ventriculomegaly, thin corpus callosum, widened cerebral subarachnoid space, and external hydrocephalus. No systematic neuroimaging study has been published, which is a notable gap given CHD3's known role in cortical layer specification.
| Feature | Phenotype 1 (Typical) | Phenotype 2 (Atypical) |
|---|---|---|
| Head size | Macrocephaly | Microcephaly |
| Growth | Overgrowth | Growth retardation |
| Hypertelorism | Present | Variable |
| DD/ID | Present | Present |
| Frequency | Majority | Minority |
SNIBCPS belongs to a growing class of NuRD-related neurodevelopmental disorders with overlapping but distinguishable features. GAND's clinical phenotype shows "substantial clinical overlap with other disorders associated with the NuRD complex that involve CHD3 and CHD4, with clinical features of hypotonia, intellectual disability" (PMID: 31949314).
| Gene | Syndrome | OMIM | Shared Features | Distinctive Features |
|---|---|---|---|---|
| CHD3 | SNIBCPS | 618205 | Macrocephaly, ID, hypotonia, facial dysmorphism | Inguinal hernias, apraxia of speech, hypersociability |
| CHD4 | Sifrim-Hitz-Weiss | 617159 | Macrocephaly, ID, hypotonia, facial dysmorphism | Skeletal anomalies, deafness, cardiac defects, dextrocardia |
| GATAD2B | GAND | 615074 | Macrocephaly, ID, hypotonia, facial dysmorphism | Epilepsy, bicuspid aortic valve |
| GATAD2A | NDD | — | ID, developmental delay | Recently described; limited data |
{{figure:differential_diagnosis_heatmap.png|caption=Figure 7. Differential diagnosis heatmap comparing SNIBCPS with related NDD syndromes including other NuRDopathies and overgrowth-ID syndromes, highlighting shared and distinguishing features}}
Estimated prevalence: 1/50,000–1/100,000 births, based on three convergent approaches:
The syndrome is described as "extremely infrequent" with "only approximately 60 cases reported" as of 2023 (PMID: 37761804), though diagnosed cases have roughly doubled since then. Significant underdiagnosis is likely given the non-specific initial presentation (developmental delay and ID).
No formal consensus guidelines exist. Based on phenotype analysis:
At Diagnosis: - Comprehensive developmental assessment - Brain MRI (ventriculomegaly, thin corpus callosum reported) - Echocardiogram (cardiac defects in ~15%) - Ophthalmologic examination (strabismus, refractive errors) - Hearing screening - Genetic counseling (de novo, low recurrence; discuss gonosomal mosaicism)
Ongoing:
| Domain | Interventions |
|---|---|
| Speech/Language | Speech-language therapy with apraxia-specific techniques (PROMPT, DTTC); AAC devices if needed |
| Developmental | Early intervention; occupational therapy; physical therapy for motor delays |
| Educational | IEP/504 plan; special education support; leverage social strengths |
| Behavioral | ASD/ADHD screening; behavioral support; social skills training |
| Neurological | EEG if seizures suspected; head circumference monitoring |
| Pain | Assess pain perception; implement safety measures for pain-insensitive individuals |
| Surgical | Evaluate for inguinal/umbilical hernia |
| Dental | Monitor for taurodontia, enamel hypoplasia |
| Model | Key Findings | Reference |
|---|---|---|
| Mouse (Chd3) | In vivo base editing rescues behavioral abnormalities | Yang et al. 2026 (PMID: 41708849) |
| Mouse (Chd3/4/5) | NuRD subunit switching regulates cortical development | Nitarska et al. 2016 (PMID: 27806305) |
| Zebrafish (chd3-KO) | Hypersociability; brain metabolomic changes | Enomoto et al. 2025 (PMID: 39988727) |
| iPSC (CHD3-depleted) | Failed CNCC specification; BMP/Wnt imbalance | Mitchell et al. 2025 (PMID: 40835974) |
NCT06860672: Dual Vector Base Editor for CHD3-R1025W
| Parameter | Detail |
|---|---|
| Phase | Early Phase 1 |
| Intervention | Single intrathecal injection of dual vector AAV-CHD3-R1025W base editor |
| Target mutation | c.3073C>T, p.(Arg1025Trp) |
| Age range | 2–10 years |
| Location | Xinhua Hospital, Shanghai Jiao Tong University |
| Status | Recruiting (since February 2025) |
| Preclinical basis | In vivo base editing rescues behavioral abnormalities in Chd3 mutant mice (PMID: 41708849) |
The preclinical study demonstrated that "neurodevelopmental disorders that arise from de novo mutations in chromatin-remodelling genes lack targeted treatments" and provided proof-of-concept for in vivo base editing as a therapeutic approach (PMID: 41708849). This represents one of the first applications of in vivo base editing for any neurodevelopmental chromatinopathy and a landmark development for the rare disease community.
{{figure:snibcps_comprehensive_summary.png|caption=Figure 8. Comprehensive single-page summary of SNIBCPS findings across genetics, phenotype, molecular mechanism, variant analysis, and therapeutic developments}}
| Paper | PMID | Key Contribution |
|---|---|---|
| 2018 landmark cohort | 30397230 | Landmark: 35 individuals, CHD3 as causal gene, functional assays |
| Pascual et al. 2023 | 37761804 | 20 additional individuals, expanded variant spectrum |
| Ionescu et al. 2025 | 40830229 | Comprehensive neurobehavioral profiling, FXS comparison |
| Yaman Bajin et al. 2024 | 39542866 | Splicing variant and arginine enrichment |
| Paper | PMID | Key Contribution |
|---|---|---|
| Mitchell et al. 2025 | 40835974 | BMP signaling in cranial neural crest specification |
| Nitarska et al. 2016 | 27806305 | Non-redundant CHD3/4/5 roles in cortical development |
| Enomoto et al. 2025 | 39988727 | Zebrafish model; hypersociability; brain metabolomics |
| Paper | PMID | Key Contribution |
|---|---|---|
| Goldfarb Yaacobi et al. 2024 | 38116750 | Biallelic variants cause severe phenotype |
| Ocay et al. 2025 | 40881826 | Pain insensitivity documentation |
| Chen et al. 2025 | 39709005 | Spastic paraplegia, ataxia, situs inversus |
| Paper | PMID | Key Contribution |
|---|---|---|
| Yang et al. 2026 | 41708849 | Preclinical base editing rescues mouse model |
| Santini et al. 2026 | 41952182 | Disease-specific episignature identified |
| Paper | PMID | Key Contribution |
|---|---|---|
| Pierson et al. 2019 | 31737996 | NuRD complex and macrocephaly-associated NDDs |
| Bain et al. 2021 | 31949314 | GATAD2B-associated NDD and NuRD overlap |
| Ivanov et al. 2007 | 18082607 | KAP1/TRIM28 SUMO-dependent CHD3 recruitment |
Limited genotype–phenotype correlation: While two phenotypic subgroups have been identified, systematic correlation between specific variant positions/types and clinical severity remains incomplete. The molecular basis for Phenotype 1 versus Phenotype 2 is unknown.
Small cohort sizes: Most studies involve 20–40 patients. Larger, longitudinal natural history studies are needed to define the full phenotypic spectrum, especially for rare features like pain insensitivity, precocious puberty, and pulmonary hypertension.
Limited functional data: Only 6 of 67+ pathogenic missense variants have been functionally characterized. The precise mechanistic impact of most variants (especially those outside the helicase domain) remains experimentally unvalidated.
No validated biomarkers: While the episignature is promising, no blood-based or imaging biomarkers exist for disease severity, progression, or treatment response.
Incomplete understanding of tissue-specific effects: CHD3 is ubiquitously expressed (highest in reproductive tissues and brain), but the contribution of non-neurological dysfunction to the phenotype is poorly characterized.
Gene therapy limitations: The current clinical trial targets only the R1025W variant. Broader therapeutic strategies (gene replacement, allele-agnostic approaches) are needed for the majority of patients.
No formal management guidelines: No GeneReviews entry or consensus management guidelines exist as of 2026.
Underdiagnosis: The estimated prevalence far exceeds diagnosed cases, indicating substantial underdiagnosis globally.
No systematic neuroimaging: Given CHD3's established role in cortical layer specification, the absence of systematic volumetric MRI, DTI, or fMRI studies is a significant gap.
Systematic genotype–phenotype study: Aggregate all published and unpublished cases (n > 100) to correlate variant position, type, and domain with clinical severity; determine the molecular basis of Phenotype 1 vs. Phenotype 2.
Expanded functional characterization: Use CRISPR-engineered iPSC lines carrying recurrent variants (R985P, R1025W, R1169Q) to assess ATPase activity, NuRD complex incorporation, BMP/Wnt signaling in neural crest differentiation, and cortical organoid development.
Episignature validation: Apply the CHD3 episignature to a larger, multi-ethnic cohort; correlate methylation patterns with clinical severity to develop a prognostic tool.
Systematic neuroimaging study: Volumetric MRI, DTI, and fMRI in a SNIBCPS cohort to characterize cortical thickness, white matter connectivity, and functional architecture — correlating with speech apraxia and cognitive severity.
Broader gene therapy strategies: Develop allele-agnostic approaches (e.g., CRISPRa to upregulate the wild-type allele, or full CHD3 gene replacement) for patients with non-R1025W variants.
Metabolomic profiling: Follow up zebrafish brain metabolomic findings by performing plasma and CSF metabolomics in SNIBCPS patients to identify biomarkers and therapeutic targets.
NuRDopathy comparative study: Direct molecular and phenotypic comparison across CHD3/CHD4/GATAD2B patients to define shared NuRD signature versus gene-specific features.
Pain insensitivity characterization: Systematic quantitative sensory testing in SNIBCPS to characterize pain pathways and inform clinical management.
Precision medicine framework: Integrate variant-specific functional data, episignature profiles, and clinical phenotyping for individualized prognosis and treatment.
Drug screening: Use CHD3-mutant cortical organoids for high-throughput screening to identify compounds restoring chromatin remodeling or compensating for downstream signaling defects (e.g., BMP pathway agonists, Wnt pathway modulators).
This comprehensive analysis identified 15 key findings characterizing Snijders Blok-Campeau Syndrome:
| # | Finding | Key Evidence |
|---|---|---|
| 1 | SNIBCPS caused by heterozygous CHD3 variants, predominantly de novo | OMIM:618205; 360 pathogenic ClinVar variants |
| 2 | Core phenotype: ID (~95%), speech delay (~90%), macrocephaly (~75%) | Synthesis of 3 cohort studies, ~100+ patients |
| 3 | CHD3 regulates BMP signaling and neural crest specification | iPSC-derived CNCC model; BMP/Wnt imbalance |
| 4 | First-in-human AAV base editing gene therapy trial | NCT06860672; R1025W-specific |
| 5 | Disease-specific DNA methylation episignature | 23-patient cohort; differentiates chromatinopathies |
| 6 | NuRDopathy disease class with overlapping features | CHD3, CHD4, GATAD2B disorders compared |
| 7 | Hypersociability validated in zebrafish model | chd3-KO zebrafish; brain metabolomic changes |
| 8 | Expanding phenotype: pain insensitivity, spastic paraplegia, etc. | Multiple case reports 2023–2025 |
| 9 | Helicase domain 4.86× enrichment; arginine 6.63× enrichment | 67 ClinVar pathogenic missense analyzed |
| 10 | Extreme gene constraint (pLI = 1.0, LOEUF = 0.263) | gnomAD v4 constraint metrics |
| 11 | Cortex-predominant brain expression gradient | GTEx v8; cortex 64.8 vs. spinal cord 12.5 TPM |
| 12 | Prevalence ~1/50,000–1/100,000; significantly underdiagnosed | Three convergent estimation methods |
| 13 | Dual mechanism: haploinsufficiency + dominant-negative | 41% LoF + 55% missense; functional assays |
| 14 | Interactome dominated by NuRD complex partners | 14/15 top interactors are NuRD components |
| 15 | AlphaFold confirms variants target well-structured catalytic domains | pLDDT +11.1 at pathogenic sites vs. background |
| Resource | Details |
|---|---|
| Simons Searchlight | Research registry for CHD3 families (simonssearchlight.org) |
| OMIM | Entry #618205 (omim.org) |
| Orphanet | ORPHA:599082 (orpha.net) |
| GARD (NIH) | Entry #13806 (rarediseases.info.nih.gov) |
| NORD | General rare disease support (rarediseases.org) |
| UNIQUE | Rare chromosome disorder support (rarechromo.org) |
| Social media groups | Parent-organized CHD3/SNIBCPS support communities |
Report generated through systematic literature review of 33 publications, database queries (gnomAD, ClinVar, UniProt, GTEx, STRING, Monarch, OMIM, ClinicalTrials.gov), AlphaFold structural analysis, and computational variant analysis across 5 investigative iterations. Analysis conducted April 2026.